CancerDrs Find care

Testicular Cancer clinical trials in Michigan

6 actively recruiting testicular cancer trials at 43 sites across Michigan.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…

Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in Michigan:
  • C S Mott Children's Hospital — Ann Arbor, Michigan
  • University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
  • Bronson Battle Creek — Battle Creek, Michigan
  • Children's Hospital of Michigan — Detroit, Michigan
  • Henry Ford Health Saint John Hospital — Detroit, Michigan
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…

Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Michigan:
  • C S Mott Children's Hospital — Ann Arbor, Michigan
  • Children's Hospital of Michigan — Detroit, Michigan
  • Henry Ford Health Saint John Hospital — Detroit, Michigan
  • Michigan State University — East Lansing, Michigan
  • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital — Grand Rapids, Michigan
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Michigan:
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
  • Trinity Health Medical Center - Brighton — Brighton, Michigan
  • Henry Ford Cancer Institute-Downriver — Brownstown, Michigan
  • Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Michigan:
  • Massive Bio SYNERGY-AI site — Ann Arbor, Michigan
  • Massive Bio SYNERGY-AI site — Lansing, Michigan
View on ClinicalTrials.gov →
Recruiting Academic/Other

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…

Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Michigan:
  • University of Michigan Health System — Ann Arbor, Michigan
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20